Back to top
January 18, 2018
FDA Review: Clobazam Oral Soluble Film for Treating Lennox-Gastaut Syndrome
Research, Treatments

The U.S. Food and Drug Administration has accepted for review a New Drug Application for clobazam Oral Soluble Film (clobazam OSF) for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or older. The target date for completion of the FDA review is the third-quarter of 2018.
 
Clobazam OSF is administered using Aquestive's PharmFilm drug delivery technology. Similar in size and thickness to a stamp, Aquestive's PharmFilm dissolves instantly after being placed on the tongue and can be administered without water.

Two multicenter controlled studies were conducted to evaluate the bioequivalence of clobazam OSF with clobazam tablets, a benzodiazepine currently on market, at the same dosage strengths. Based on the studies, clobazam OSF was demonstrated to be bioequivalent to clobazam tablets and have comparable safety.

Learn More

 

Related News

August 9, 2018
Crowdsourced Algorithms Predict Epilepsy Seizures

Thanks to the crowdsourcing of more than 10,000 algorithms from around the world, epileptic seizure prediction is possible in a wider range of...

Read More
August 9, 2018
Environmental Enrichment Alleviates Cognitive and...

[Researchers state] these findings suggest that environmental enrichment effectively ameliorates cognitive and behavioral deficits in EL mice....

Read More
August 9, 2018
Compound from Spider Venom Reduces Seizure Susceptibility,...

A CURE Grantee and other researchers discovered that a compound isolated from spider venom called Hm1a helps reduce seizure susceptibility and...

Read More